Shang Xiaoling, Song Xingguo, Wang Kangyu, Yu Miao, Ding Shanshan, Dong Xiaohan, Xie Li, Song Xianrang
Department of Clinical Laboratory, Cheeloo College of Medicine, Shandong Cancer Hospital and Institute, Shandong University, Jinan, 250012, Shandong, China.
Department of Clinical Laboratory, Shandong First Medical University and Shandong Academy of Medical Sciences, Shandong Cancer Hospital and Institute, 440 Ji-Yan Road, Jinan, 250117, Shandong, People's Republic of China.
Cancer Cell Int. 2021 Jan 18;21(1):56. doi: 10.1186/s12935-020-01744-4.
Increasing evidence has demonstrated that snoRNAs play crucial roles in tumorigenesis of various cancer types. However, researches on snoRNAs in ccRCC were very little. This study mainly aimed to validate the differential expression and the potential diagnostic value of SNORD63 and SNORD96A in ccRCC.
SnoRNAs expression was downloaded from the SNORic and TCGA database including 516 patients with ccRCC and 71 control cases. SNORD63 and SNORD96A expression were further detected in 54 tumor and adjacent FFPE ccRCC tissues, 55 plasma and 75 urinary sediment of ccRCC patients. Then, differential expression and diagnostic value of SNORD63 and SNORD96A were further calculated.
SNORD63 and SNORD96A expression were significantly increased in ccRCC tissues compared with normal tissues from the TCGA database (both, P < 0.0001). In addition, we found that SNORD63 and SNORD96A localized in plasma and US stably after treating with RNase A. Meanwhile, SNORD63 and SNORD96A in FFPE and US were elevated in ccRCC patients (all, P < 0.0001). However, plasma SNORD63 expression had no significance while SNORD96A significantly increased in plasma of ccRCC patients. Notably, the AUC of SNORD63 in US was 0.7055, by comparison the AUC of plasma SNORD63 was only 0.5161. However, the AUC of plasma SNORD96A was up to 0.8909, by comparison the AUC of SNORD96A in US was 0.6788. Interestingly, the AUC of plasma SNORD96A in early stage ccRCC was highly up to 0.9359.
Our findings revealed that SNORD63 in US and SNORD96A in plasma could act as the promising non-invasive diagnostic biomarkers for ccRCC patients.
越来越多的证据表明，小核仁RNA（snoRNAs）在多种癌症类型的肿瘤发生中起关键作用。然而，关于透明细胞肾细胞癌（ccRCC）中snoRNAs的研究非常少。本研究主要旨在验证SNORD63和SNORD96A在ccRCC中的差异表达及潜在诊断价值。
从小核仁RNA信息库（SNORic）和癌症基因组图谱（TCGA）数据库下载snoRNAs表达数据，包括516例ccRCC患者和71例对照病例。进一步检测54例ccRCC肿瘤及癌旁福尔马林固定石蜡包埋（FFPE）组织、55例ccRCC患者血浆和75例尿液沉渣中SNORD63和SNORD96A的表达。然后，进一步计算SNORD63和SNORD96A的差异表达及诊断价值。
与TCGA数据库中的正常组织相比，ccRCC组织中SNORD63和SNORD96A的表达显著增加（均P < 0.0001）。此外，我们发现用核糖核酸酶A处理后，SNORD63和SNORD96A稳定存在于血浆和尿液沉渣中。同时，ccRCC患者FFPE组织和尿液沉渣中的SNORD63和SNORD96A升高（均P < 0.0001）。然而，ccRCC患者血浆中SNORD63表达无统计学意义，而SNORD96A显著增加。值得注意的是，尿液沉渣中SNORD63的曲线下面积（AUC）为0.7055，相比之下血浆中SNORD63的AUC仅为0.5161。然而，血浆中SNORD96A的AUC高达0.8909，相比之下尿液沉渣中SNORD96A的AUC为0.6788。有趣的是，早期ccRCC患者血浆中SNORD96A的AUC高达0.9359。
我们的研究结果表明，尿液沉渣中的SNORD63和血浆中的SNORD96A可作为ccRCC患者有前景的非侵入性诊断生物标志物。
